NasdaqCM:AKBABiotechs
Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives
Akebia Therapeutics (AKBA) opened Q1 2026 with total revenue of US$53.5 million and a basic EPS loss of US$0.03, alongside a quarterly net loss of US$9.1 million. On a trailing twelve month basis, revenue was US$232.4 million with a net loss of US$20.5 million and basic EPS of US$0.08. Over the last five reported quarters, the company has seen quarterly revenue range between US$46.5 million and US$62.5 million, with basic EPS moving from a profit of US$0.03 in Q1 2025 to losses such as...